Apogee Therapeutics announced positive interim Phase 1 results for APG990, a novel, half-life extended OX40L antibody, demonstrating an approximately 60-day half-life. This achievement paves the way for a Phase 1b head-to-head study of APG279 (a combination of APG777 and APG990) against Dupixent, planned for later this year with results expected in the second half of 2026. Preclinical toxicology studies of the combination therapy and the positive APG990 results support the advancement of this program.
This news is potentially transformative for the treatment of atopic dermatitis (AD) and other inflammatory and immunology (I&I) conditions. The extended half-life of APG990 suggests the possibility of infrequent dosing—every three or six months—which could significantly improve patient adherence and convenience. The combination therapy, APG279, aims to address the complex nature of AD by inhibiting multiple inflammatory pathways (Types 1, 2, and 3), potentially offering superior efficacy compared to existing therapies that primarily target the Type 2 pathway.
Interim Phase 1 pharmacokinetic data revealed a 60-day half-life for APG990 across all tested doses. This supports the potential for infrequent dosing with a small injection volume (2 mL) for the combined APG279 therapy. APG990 was well-tolerated in the Phase 1 trial, with no serious adverse events reported. Preclinical combination studies of APG777 and APG990 showed no safety concerns and indicated a potential for enhanced efficacy compared to the individual agents.
The extended half-life, favorable tolerability profile, and potential for enhanced efficacy of APG990 and the APG279 combination position Apogee Therapeutics to become a leader in the AD treatment landscape. The upcoming head-to-head trial against Dupixent will be crucial in determining the clinical benefit of this novel approach and could reshape the treatment paradigm for AD and potentially other I&I diseases.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
